Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 27 Oct 2022
Cheaper medicines legislation passed
27 October 2022 - The Australian Government’s legislation, which will see millions of Australians pay 29% less for scripts with the ...
Posted by Michael Wonder on 27 Oct 2022
Independent chair of health technology assessment review will drive major reform of Australia’s health system
27 October 2022 - Medicines Australia welcomes the appointment of Adjunct Professor Debora Picone AO as independent Chair of the ...
Posted by Michael Wonder on 27 Oct 2022
Reference Committee for the health technology assessment policy and methods review
27 October 2022 - On 6 September 2021, the Commonwealth entered into a new Strategic Agreement in relation to reimbursement, ...
Posted by Michael Wonder on 27 Oct 2022
Health Canada approves Kerendia (finerenone) as an adjunct to standard of care therapy in adults with chronic kidney disease and type 2 diabetes
26 October 2022 - The approval is based on the results of the Phase 3 FIDELIO-DKD and FIGARO-DKD trial investigating the ...
Posted by Michael Wonder on 27 Oct 2022
HTA review and chair committee
27 October 2022 - The Government today announced the appointment of Adjunct Professor Debora Picone AO as Chair of the Health ...
Posted by Michael Wonder on 26 Oct 2022
US FDA delays panel meet on Perrigo's OTC birth control pill
26 October 2022 - The US FDA has delayed a meeting of its advisory panel to discuss Perrigo's over the ...
Posted by Michael Wonder on 26 Oct 2022
Seres Therapeutics announces FDA acceptance of biologics license application for investigational microbiome therapeutic SER-109 for recurrent C. difficile infection for priority review
26 October 2022 - PDUFA target action date is 26 April 2023, with anticipated launch soon thereafter. ...
Posted by Michael Wonder on 26 Oct 2022
Germany significantly tightens drug pricing and reimbursement laws
26 October 2022 - The German regulation of pricing and reimbursement of pharmaceuticals is probably one of the most complicated legal ...
Posted by Michael Wonder on 26 Oct 2022
The Meningitis Foundation says PHARMAC proposal to partially fund a meningococcal B vaccine will not work
26 October 2022 - Meningitis Foundation says Pharmac must make vaccine available to all young people, not just those in ...
Posted by Michael Wonder on 26 Oct 2022
MSAC Secretariat tweaks the agenda for Dec 2022 PASC meeting
26 October 2022 - The PASC will consider one more application. ...
Posted by Michael Wonder on 26 Oct 2022
CorVista Health receives breakthrough device designation for the CorVista system
25 October 2022 - CorVista Health announces that the US FDA has granted breakthrough device designation for the CorVista System as ...
Posted by Michael Wonder on 26 Oct 2022
PHARMAC funds ramipril for people with high blood pressure
26 October 2022 - PHARMAC today has announced the decision to fund ramipril (branded as Tryzan), an angiotensin-converting enzyme (ACE) inhibitor ...
Posted by Michael Wonder on 25 Oct 2022
FDA panel vote highlights accelerated approval concerns
25 October 2022 - Last week’s overwhelming vote in favour of pulling preterm-birth drug Makena from the market — and ...
Posted by Michael Wonder on 25 Oct 2022
IntelGenx receives FDA GDUFA date for Xiromed partnered development candidate, buprenorphine buccal film
25 October 2022 - IntelGenx today announced that its previously undisclosed development candidate, buprenorphine buccal film, for which an abbreviated ...
Posted by Michael Wonder on 25 Oct 2022
A perspective on life cycle health technology assessment and real world evidence for precision oncology in Canada
25 October 2022 - Health technology assessment can be used to make healthcare systems more equitable and efficient. Advances in precision ...